Semaxanib, also known as SU5416, is a quinolone derivative with potential antineoplastic activity. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells.
Related Prodcuts:
LY2874455; ZM-306416; ZM323881; Tyrphostin A9; Orantinib; Brivanib; Foretinib; SU5402; SAR131675; Lucitanib; Apatinib; SKLB610; Altiratinib; SGI-7079; AZD2932